Series A · Healthtech · London, United Kingdom · Founded 2019 · 60+ employees
SAVA is developing breakthrough wearable biosensor technology that monitors health biomarkers in real-time through painless microsensors placed just beneath the skin. The London-based startup emerged from stealth in 2024 with their first product targeting glucose monitoring for diabetes patients, claiming their devices are significantly cheaper and less invasive than current CGM solutions. Recent clinical trials involving 50 diabetes patients showed their technology delivered accurate glucose readings for up to 10 days, matching performance of leading CGMs without the invasiveness. The modular platform can potentially monitor multiple biomarkers simultaneously, positioning SAVA to expand beyond diabetes into broader health monitoring applications.